Cartesian Therapeutics (RNAC) Retained Earnings (2016 - 2025)
Historic Retained Earnings for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to -$729.8 million.
- Cartesian Therapeutics' Retained Earnings fell 703.74% to -$729.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$729.8 million, marking a year-over-year decrease of 703.74%. This contributed to the annual value of -$692.1 million for FY2024, which is 1259.65% down from last year.
- Cartesian Therapeutics' Retained Earnings amounted to -$729.8 million in Q3 2025, which was down 703.74% from -$693.9 million recorded in Q2 2025.
- Cartesian Therapeutics' 5-year Retained Earnings high stood at -$392.9 million for Q2 2022, and its period low was -$729.8 million during Q3 2025.
- Over the past 5 years, Cartesian Therapeutics' median Retained Earnings value was -$437.0 million (recorded in 2023), while the average stood at -$528.9 million.
- In the last 5 years, Cartesian Therapeutics' Retained Earnings skyrocketed by 943.74% in 2022 and then crashed by 6118.58% in 2024.
- Quarter analysis of 5 years shows Cartesian Therapeutics' Retained Earnings stood at -$430.3 million in 2021, then grew by 8.22% to -$394.9 million in 2022, then tumbled by 55.63% to -$614.6 million in 2023, then decreased by 12.6% to -$692.1 million in 2024, then decreased by 5.45% to -$729.8 million in 2025.
- Its last three reported values are -$729.8 million in Q3 2025, -$693.9 million for Q2 2025, and -$709.8 million during Q1 2025.